





EDA[™]Advancing Patient Safety

IN SYNC WITH YOUR NEED FOR HIGH-SPEED SCANNING AND SEAMLESS WORKFLOW

EDA[™] extravasation detection technology* is designed to aid in the detection of potentially harmful extravasations. By notifying and pausing injections if a clinically significant variation is detected, EDA helps technologists realize the full potential of high scanning speeds, giving them the confidence that their good technique is backed by leading-edge technology.

IN SYNC WITH BEST PRACTICES FOR IMPROVING CLINICAL OUTCOMES

Duke University Medical Center data review of EDA technology[†]

Duke University Medical Center reviewed data collected over a 15-month period using the EmpowerCTA® Contrast Injection System for radiology, emergency, and outpatient care services. The review concluded that extravasation detection provides important benefits for both patients and CT staff, including:

- Minimizing contrast media (vesicant) extravasation and resulting skin damage
- Maximizing the CT staff's ability to complete important diagnostic imaging procedures
- Quickly determining when there is no extravasation so that departmental workflow can continue without interruption
- * EDA is designed to aid in the detection of extravasations and is not intended as a substitute for proper patient monitoring and good clinical practice.

* A Retrospective Review: Duke University Medical Center's Experience with the Extravasation Detection Accessory (EDA) Technology, Donna Parker, RT, co-director, Duke CT Institute, Chief Technologist, Department of Radiology at Duke University Medical Center.





MR Suite

Nuclear Suite

Moving to the **rhythm** of your workflow



IN SYNC WITH YOUR NEED FOR PATIENT SAFETY

Detecting extravasation is critically important to patient safety during high injection flow rates:

20 mL bolus at 2.0 mL/sec Extravasation clinically significant, but not yet serious

40 mL bolus at 4.0 mL/sec Serious extravasation could occur with 40 mL bolus injected

100 mL bolus at 10.0 mL/sec Maximum rate could create a large 100 mL extravasation

EDA extravasation detection technology is one of several exclusive integrated, informative, and intuitive features of the EmpowerCTA® Contrast Injection System designed for optimal workflow and operational lab efficiency.

100 mL BOLUS

EmpowerCTA is designed for the administration of nonionic and ionic compounds and flushing media in conjunction with computed tomography (CT) scanning of the body. The EDA is intended to detect extravasations of ionic and nonionic contrast media during powered CT contrast injections.

Bracco Diagnostics Inc. Distributed by Bracco Diagnostics Inc. 107 College Road East Princeton, New Jersey 08540 Phone: (800) 631-5245 Fax: (609) 514-2424

Customer Service:

1-877-BRACCO 9 (1-877-272-2269) Professional Services:

1-800-257-5181 (option 1)

Email: BRACCO@diag.bracco.com Website: usa.braccoimaging.com

Committed **to Science**, Committed **to You**[™]. ACIST Medical Systems, Inc. Manufactured by ACIST Medical Systems, Inc. Corporate Headquarters 7905 Fuller Road Eden Prairie, Minnesota 55344 Phone: (952) 941-3507 Fax: (952) 942-4648 Toll-free in U.S.: 1-888-667-6648 Website: www.acist.com ACIST and EmpowerCTA are registered trademarks of ACIST Medical Systems, Inc. EDA is a trademark of ACIST Medical Systems, Inc.

40 mL

BOLUS

Not all products available in all global markets.

© 2010 Bracco Diagnostics Inc. All Rights Reserved. Printed in USA 10-062210B



20 mL

BOLUS